Chimeric Norovirus VP1 Proteins for Rapid Vaccine Adaptation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The development of an effective vaccine against norovirus has been hindered by complex antigenic diversity among strains, sequential replacement of dominant circulating strains, lack of a cell culture model, and absence of an animal model for human noroviruses, making it challenging to create a vaccine that is broadly effective and adaptable to emerging variants.
Innovation Solution
The use of chimeric norovirus VP1 proteins, where the S-domain from one strain is combined with the P-domain from another, allows for the rapid generation of immunogenic compositions that can self-assemble into virus-like particles (VLPs), enabling the production of stable and efficiently prepared norovirus immunogenic materials from various strains, including new field and clinical isolates.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If traditional vaccine development methods are used, then vaccine composition can be prepared, but the process is slow and cannot keep pace with emerging norovirus strains
Solution Approach 1:
The VP1 capsid protein is segmented into two functional domains: the S-domain (residues 1-225) which forms the core structure, and the P-domain (residues 231-530) which contains antigenic epitopes. This segmentation allows independent manipulation of each domain to create chimeric proteins that combine the stable core of one strain with the antigenic surface of another, enabling rapid adaptation to emerging strains while maintaining production efficiency
Solution Approach 2:
Chimeric VP1 proteins are constructed by combining domains from different norovirus strains (e.g., S-domain from strain A with P-domain from strain B). These composite proteins self-assemble into virus-like particles that exhibit both the structural stability of the parent strain and the antigenic properties of the target emerging strain, achieving both productivity and adaptability
2Reliability
If monovalent VLPs from a single strain are used, then production is simple and stable, but effectiveness against diverse norovirus strains is limited
Solution Approach 1:
The chimeric VP1 protein design allows a single VLP construct to serve multiple functions: the S-domain provides universal structural stability and self-assembly capability, while the P-domain can be customized to target specific emerging strains. This multi-functionality enables the vaccine platform to maintain reliability through the conserved S-domain while achieving adaptability through variable P-domains from different strains
3Ease of operation
If the P2 domain is targeted for antigenic variation, then immune reactivity is enhanced, but sequence variability makes consistent production difficult
Solution Approach 1:
The P2 subdomain (residues 279-405) within the P-domain is identified as the hypervariable region containing critical antigenic epitopes. By targeting only this specific local region for variation while keeping the rest of the P-domain and the entire S-domain constant, the invention achieves enhanced immune reactivity through P2 diversity while maintaining production consistency through the stable framework of the conserved regions
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the rapid customization of norovirus vaccines to address emerging strains, improving the speed, reliability, and stability of vaccine composition, potentially leading to better protection against a broad range of norovirus strains.
Implementation Method 1
When VP1 is expressed recombinantly, it can self-assemble into an icosahedral capsid structure that lacks a viral genome and is known as virus-like particle (VLP)
Data Source
AI summary
The invention relates to chimeric norovirus VP1 proteins containing the S-domain of VP1 of a first norovirus strain and a P-domain that contains at least a portion of the P-domain of VP1 of a second norovirus strain. The invention also relates to nucleic acids that encode the chimeric VP1 proteins, virus-like particles that contain a chimeric norovirus VP1 protein, and to immunogenic compositions.